Hypertension is an important global health issue, affecting around 40% of adults aged 25 and over. It is characterised by a persistently elevated arterial blood pressure and is divided into two main categories: primary hypertension and secondary hypertension.
Primary hypertension is the most common form, affecting over 90% of hypertensive patients. It is defined as having no identifiable cause and is likely to be the consequence of an interaction between environmental and genetic factors.
Secondary hypertension, which is far less common, is a type of hypertension with a known underlying cause. It can be the side effect of a medication or the symptom of conditions such as endocrine disease, kidney disease and tumours.
There is also a subtype of hypertension known as pulmonary hypertension, which is characterised by increased arterial blood pressure within the lungs that can cause symptoms such as dyspnea, syncope, lethargy, chest pain, oedema, and tachycardia.
While it is rarely accompanied by symptoms, long-term hypertension is a major risk factor for a large range of diseases including coronary heart disease, stroke, heart failure, atrial fibrillation, chronic kidney disease and dementia.
The goal of hypertension treatment is to lower the high blood pressure and protect organs from damage. Treatments primarily involve lifestyle changes and drug therapy such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).
To find out more, visit our Cardiovascular Metabolism Learning Zone, which has further information on hypertension including the renin-angiotensin system as well as expert videos, webcasts and quick facts about hypertension.
You may be interested in...
The Union-North America Region (NAR) is the regional arm of the International Union against Tuberculosis and Lung Disease (The Union), a global public health organization with the vision to provide health solutions to the poor.
28th Conference On Retrovirus And Opportunistic Infections 2021
CROI is the preeminent meeting in the world and attracts more than 4,000 research leaders from nearly 90 countries and nearly half of CROI attendees come from outside the United States. In recent years, more than 1000 abstracts have been selected for presentation at CROI.
Your peers are looking at...
Featured Learning Zones
Related news and insights
Merck Inc and Pfizer announced the presentation of results from the Phase III VERTIS CV cardiovascular (CV) outcomes trial that evaluated Steglatro (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in more than 8,200 patients with type 2 diabetes and atherosclerotic CV disease across 531 centers in 34 countries.
Senolytics are small molecules under basic research to determine if they can selectively induce death of senescent cells (damaged cells that do not die but persist and become toxic to the cells around them). Cellular senescence has been shown to drive multiple age-related diseases, including idiopathic pulmonary fibrosis (IPF), a chronic, irreversible and progressive disease that results in scarring of the lungs.